Jones Day‘s Tokyo office regularly advises trading companies on outbound M&A. The department is active in life sciences and energy M&A transactions. Sydney-based Chris Ahern heads up the team and has a strong track record of handling large cross-border M&A deals and court-approved mergers by scheme of arrangement. New York-qualified lawyer Benjamin Lang advises on the full breadth of transactional matters for life sciences companies, from public and private M&A and spin-outs to licensing transactions. Yuichiro Mori draws on over three decades of experience to advise Japanese and international clients on buyouts, joint ventures, and business restructurings.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Billing & efficiency
Testimonials
Collated independently by Legal 500 research team.
- 'Practical, easy to work with.'
- 'Experienced, sensitive to client needs.'
- 'With a global one-team structure, Jones Day is an organisation that can provide detailed consideration and appropriate legal advice to the clients in cooperation with lawyers in each country, even for global transaction cases.'
- 'Benjamin Lang has experience in various types of M&A and can provide accurate advice not only from a corporate perspective but also in collaboration with lawyers in various fields such as security lawyers, antitrust lawyers, and tax lawyers. He is also fluent in Japanese, which is a great advantage.'
Key clients
- ENEOS Corporation
- Marelli Holdings Co., Ltd.
- Marubeni Corporation
- PAG
- Sanken Electric Co., Ltd.
- SIOS Corporation
- Sumitomo Pharma Co., Ltd.
- Wabtec Corporation
Work highlights
Advised ENEOS Corporation on its minority investment into C2X Ltd.
Advised Marubeni Corporation on its acquisition of Gemsa Enterprises, LLC.
Advised Sumitomo Pharma Co., Ltd. on its co-promotion agreement with Janssen Pharmaceutical K.K. for the long-acting antipsychotic medication XEPLION® and XEPLION TRI® in Japan.
Practice head
Chris J. Ahern
Other key lawyers
Benjamin Lang; Yuichiro Mori